Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no furthrer therapy complete surgery [Tumori stromali del tratto gastrointestinale (GIST), localizzati, completamente asportati che esprimono recettore Kit: uno studio clinico controllato, randomizzato, con terapia adiuvante con Imatinib mesylate (Glivec) versus nessuna ulteriore terapia dopo chirurgia radicale].

Trial Profile

Intermediate and high risk localized, completely resected, gastrointestinal stromal tumors (GIST) expressing KIT receptor: a controlled randomized trial on adjuvant Imatinib mesylate (Glivec) versus no furthrer therapy complete surgery [Tumori stromali del tratto gastrointestinale (GIST), localizzati, completamente asportati che esprimono recettore Kit: uno studio clinico controllato, randomizzato, con terapia adiuvante con Imatinib mesylate (Glivec) versus nessuna ulteriore terapia dopo chirurgia radicale].

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Sep 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 15 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 14 Sep 2017 The trial has been completed in Germany.
    • 16 Nov 2015 Interim results published in the Journal of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top